Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · Transpact Enterprises Limited · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Transpact Enterprises Limited
BSE: 542765
Healthcare › Healthcare › Healthcare Equipment & Supplies › Medical Equipment & Supplies

Transpact Enterprises Limited

StateQ4 FY26 filed
Last close · 27 Oct 2026₹100.00
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA436.7 · — · —

Operates a small consulting, advisory and financial services business, listed on the BSE Startup Platform. Revenue from operations came in at Rs 18 lakhs in FY26, up from Rs 8.25 lakhs in FY25 and nil in FY24. The company reported a net profit of Rs 8.64 lakhs in FY26 against Rs 0.90 lakhs in FY25, although operating cash flow was negative at Rs 0.55 lakhs. Total assets stood at Rs 77.81 lakhs at end-FY26 with cash balances of Rs 1.36 lakhs and no capex during the year. The board has approved a special resolution to change the company's name to 'ACME Fintech Limited' or 'ACME Global' to reflect what management describes as its fintech, broking and advisory focus. Employee costs at 11.3% of revenue and other operating expenses at 16.4% are the main cost items; materials and capex were nil in FY26. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Consulting, advisory and financial services. Micro-cap services and advisory entity on the BSE Startup Platform

What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.

Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)

₹ crore · standaloneFY22FY23FY24FY25FY26
Revenue00000
EBITDA (ex other income)———0—
margin %———50.2—
Owners' profit———0—
EPS, as reported (₹)(6.23)(1.70)0.000.020.22
ROE % · ROCE %— · (39.4)— · (12.0)— · (20.4)2.0 · 0.9— · 14.6
Debt / equity (x)———0.22—
Cash from operations(0)01(0)0
Capex———00
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Transpact Enterprises Limited · 28 October 2026Page 2 of 3

Exhibit 2: Quarterly performance, last 8 quarters

₹ croreQ2 FY23Q4 FY23Q2 FY24Q4 FY24Q2 FY25Q4 FY25Q2 FY26Q4 FY26
Revenue00000000
Profit before tax0(0)(0)(0)(0)000
Net profit0————0——
EPS (₹)1.22(1.70)(1.21)0.00(0.13)0.130.130.10
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.

Exhibit 3: Peers — basic industry group, by market cap

CompanyM.cap ₹ crP/EP/BEV/EBITDAROE %ROCE %Rev CAGR 5y %EBITDA m. %
POLY MEDICURE LIMITED14,93047.44.7427.410.212.619.030.2
FISCHER MEDICAL VENTURE L1,65110.54.2930.98.111.3—15.5
TARSONS PRODUCTS LIMITED1,593143.32.5113.82.32.4—29.0
LAXMI DENTAL LIMITED99632.04.0821.411.811.0—22.3
Hemant Surgical Industries Lim74328.4———16.7——
FABTECH TECHNOLOGIES LTD5669.21.359.19.110.7—9.9
Prevest Denpro Limited45515.4———21.9——
NURECA LIMITED29660.71.6435.61.22.7(7.2)13.0
Source: exchange data and filed statements via the screener; multiples at current prices.

Exhibit 4: Where the company sits in its group

MetricCompanyGroup medianRankBetter than
P/E (TTM)436.721.016 of 160%
ROCE14.611.36 of 1769%
Market cap416417 of 170%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Transpact Enterprises Limited · 28 October 2026Page 3 of 3

Exhibit 5: Filings of the last 90 days, with the measured price reaction

Date · filingCategoryImportanceNext day %5-day %
13 Oct 2026 · Reg 74(5) compliance certificate for Q2 FY26-27complianceminimal——
30 Sept 2026 · Scrutinizer's Report: All Resolutions Passed at 13th AGMcomplianceminimal——
29 Sept 2026 · Transpact Enterprises 13th AGM held on Sep 29, 2026; key resolutions passedboard shareholder meetingsmedium——
10 Sept 2026 · Book closure for 13th AGM on September 29, 2026board shareholder meetingslow——
5 Sept 2026 · Notice of 13th AGM on 29 September 2026 at 4:00 PM via video conferenceboard shareholder meetingslow——
5 Sept 2026 · Transpact Enterprises FY26 Annual Report: Revenue up 118%, PAT jumps to Rs 8.04 lakhresultshigh——
4 Sept 2026 · Revised Board Meeting Outcome: AGM and Annual Report Approvedmanagement changesmedium——
4 Sept 2026 · Board meeting outcome - Annual Report approved, 13th AGM finalizedresultshigh——
1 Sept 2026 · Board Meeting on 4 Sep 2026 to approve FY26 results and AGMresultslow——
14 Jul 2026 · Reg 74(5) Certificate for Q1 FY27 Filedcomplianceminimal——
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).

How to read this document

Where a broker report showsThis document showsWhy
A rating (BUY / ADD / REDUCE / SELL)A state: the latest filed quarter and the measured reactionsan event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upsideThe current price and the multiples against the groupa target is a forecast; a multiple is a measurement
Estimate years marked EMore audited years; no estimatesMarketPing publishes no forecasts — your own model lives on the Models page

Sources, method and disclosures

This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.

Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in